Nuvation Bio Inc. (NYSE: NUVB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.44 | Insider Own | 43.75% | Shs Outstand | 347.20M | Perf Week | -3.62% |
| Market Cap | 2.03B | Forward P/E | - | EPS next Y | -0.19 | Insider Trans | -0.39% | Shs Float | 253.59M | Perf Month | -19.42% |
| Enterprise Value | 1.62B | PEG | - | EPS next Q | -0.12 | Inst Own | - | Short Float | 21.40% | Perf Quarter | 5.22% |
| Income | -151.00M | P/S | 11.95 | EPS this Y | 10.86% | Inst Trans | - | Short Ratio | 8.02 | Perf Half Y | 37.32% |
| Sales | 170.00M | P/B | 8.00 | EPS next Y | 50.43% | ROA | -20.12% | Short Interest | 54.26M | Perf YTD | -34.71% |
| Book/sh | 0.73 | P/C | 3.07 | EPS next 5Y | - | ROE | -49.73% | 52W High | 9.75 -40.00% | Perf Year | 79.45% |
| Cash/sh | 1.90 | P/FCF | - | EPS past 3/5Y | - | ROIC | -20.68% | 52W Low | 2.99 95.65% | Perf 3Y | 306.25% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 93.94% | Volatility | 4.73% 4.54% | Perf 5Y | -37.37% |
| Dividend TTM | - | EV/Sales | 9.54 | EPS Y/Y TTM | 79.15% | Oper. Margin | -81.00% | ATR (14) | 0.34 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.14 | Sales Y/Y TTM | 2025.00% | Profit Margin | -88.19% | RSI (14) | 39.14 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.37 | EPS Q/Q | 11.76% | SMA20 | -10.09% | Beta | 1.58 | Target Price | 20.50 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 540.00% | SMA50 | -8.88% | Rel Volume | 0.65 | Prev Close | 6.07 |
| Employees | 305 | LT Debt/Eq | 0.01 | Earnings | Nov 02 | SMA200 | -0.92% | Avg Volume | 6.81M | Price | 5.85 |
| IPO Date | Aug 26, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -5.89% 25.68% | Net Debt/EBITDA | 0.05 | Volume | 4,433,817 | Change | -3.62% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $19 → $20 |
| Jul-27-26 | Reiterated | HC Wainwright & Co. | Buy | $17 → $21 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $12 → $19 |
| Jan-27-26 | Reiterated | Truist Financial | $11 → $13 | |
| Jan-21-26 | Reiterated | RBC Capital | Outperform | $5.00 → $12 |
| Jan-12-26 | Reiterated | HC Wainwright & Co. | Buy | $18 → $17 |
| Jan-07-26 | Reiterated | UBS | $10 | |
| Dec-11-25 | Reiterated | HC Wainwright & Co. | Buy | $10 → $18 |
| Dec-01-25 | Reiterated | HC Wainwright & Co. | Buy | $7.00 → $10 |
| Nov-24-25 | Initiated | Truist | Buy | $11 |
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 170 | 63 | 8 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 10 | 8 | 7 | — | — | — | — | — | — | |
| Gross Profit | 160 | 54 | 1 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 158 | 152 | 69 | — | — | — | — | — | — | |
| Research and Development | 129 | 115 | 524 | — | — | — | — | — | — | |
| Other Operating Expense | 10 | 1 | 0 | — | — | — | — | — | — | |
| Operating Income | -137 | -213 | -593 | — | — | — | — | — | — | |
| Interest Expense | 28 | 14 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 22 | 25 | — | — | — | — | — | — | |
| Net Income Before Taxes | -151 | -205 | -568 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -151 | -205 | -568 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -151 | -205 | -568 | — | — | — | — | — | — | |
| Net Income | -151 | -205 | -568 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.43 | -0.60 | -2.11 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.43 | -0.60 | -2.11 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.44 | -0.60 | -2.11 | — | — | — | — | — | — | |
| EBITDA | -127 | -189 | -567 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 12.01 | 48.64 | 89.44 | — | — | — | — | — | — | |
| Gross Margin | 94.12 | 85.71 | 12.50 | — | — | — | — | — | — | |
| Operating Margin | -80.59 | -338.10 | -7,412.50 | — | — | — | — | — | — | |
| Net Margin | -88.82 | -325.40 | -7,100.00 | — | — | — | — | — | — | |
| Shares Outstanding | 349 | 342 | 269 | — | — | — | — | — | — | |
| Market Capitalization | 2,042 | 3,064 | 716 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Aug 19 '26 | Option Exercise | 1.87 | 100,000 | 187,000 | 100,000 | Aug 21 |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Aug 19 '26 | Sale | 7.09 | 100,000 | 709,240 | 0 | Aug 21 |
| Sauvage Philippe | Chief Financial Officer | Jul 15 '26 | Option Exercise | 2.17 | 40,000 | 86,800 | 54,131 | Jul 17 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Jun 23 '26 | Sale | 6.02 | 63,000 | 379,191 | 53,000 | Jun 24 |
| Sauvage Philippe | Chief Financial Officer | Jun 23 '26 | Option Exercise | 2.17 | 47,668 | 103,440 | 60,341 | Jun 24 |
| Sauvage Philippe | Chief Financial Officer | Jun 23 '26 | Sale | 6.01 | 47,668 | 286,370 | 12,673 | Jun 24 |
| Markel Stacy | CHIEF PEOPLE OFFICER | Jun 23 '26 | Option Exercise | 1.83 | 125,000 | 229,250 | 157,591 | Jun 24 |
| Markel Stacy | CHIEF PEOPLE OFFICER | Jun 23 '26 | Sale | 6.03 | 125,000 | 753,188 | 32,591 | Jun 24 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Jun 23 '26 | Option Exercise | 2.93 | 63,000 | 184,590 | 116,000 | Jun 24 |
| Mashal Robert | Director | Jun 09 '26 | Buy | 4.73 | 25,000 | 118,250 | 225,000 | Jun 11 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 17 '26 | Option Exercise | 2.93 | 36,750 | 107,678 | 89,750 | Apr 21 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 17 '26 | Sale | 5.01 | 36,750 | 184,279 | 53,000 | Apr 21 |
| Liu Dongfang | CHIEF MEDICAL OFFICER | Apr 17 '26 | Option Exercise | 1.94 | 50,000 | 97,000 | 68,000 | Apr 21 |
| Liu Dongfang | CHIEF MEDICAL OFFICER | Apr 17 '26 | Sale | 5.02 | 50,000 | 251,000 | 18,000 | Apr 21 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 06 '26 | Option Exercise | 1.91 | 200,000 | 381,000 | 253,000 | Apr 08 |